Effects of 3% Diquafosol Ophthalmic Solution for Patients After Pterygium Surgery

Effects and Safety of 3% Diquafosol Ophthalmic Solution on Ocular Surface and Tear Film Recovery for Patients After Pterygium Surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026901

Enrollment

Unknown

Registered

2019-10-26

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium

Interventions

1:3% diquafosol ophthalmic solution

2:0.1% sodium hyaluronate ophthalmic solution

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. All patients with primary pterygium; 2. Any gender, aged 18-70 years; 3. Voluntary to participate, and sign the consent form; 4. Patients with bilateral pterygium choose the lager one; 5. Have not participate in other clinical research for the past two weeks.

Exclusion criteria

Exclusion criteria: 1. Recurrent pterygium/ Pseudopterygium; 2. Large pterygium >= 5mm in horizontal or vertical diameter; 3. Combined with other eye diseases except cataract; 4. BUT=0s or Schirmer test 30 points, including flaky staining fusion or filaments; 6. Be allergic to any component of experimental drug; 7. Pregnant women or lactating women or plan to pregnant recently; 8. A history of systemic diseases, such as autoimmune diseases and diabetes mellitus; 9. History of any ocular surgery or ocular trauma in the last 6 months; 10. Contact lens wear; 11. Can not promise to take medication as required or follow up during the clinical trial; 12. With any reason that researcher consider as unsuitability of the clinical trial; 13. Taking concomitant medications that could cause dry eye (eg. antihistamines, antidepressants, decongestants, anticholinergic drugs).

Design outcomes

Primary

Measure	Time frame
Ocular surface index;Tear film examination;Corneal staining;Slit-lamp examination;	—

Secondary

Measure	Time frame
Visual acuity;IOP;Direct ophthalmoscope;Questionnaire;	—

Countries

China

Contacts

Public ContactLingyi Liang

Zhongshan Ophthalmic Center, Sun Yat-Sen University

lingyiliang@qq.com+86 13829738319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026